METTL14 and Ewing sarcoma: METTL14 and TYHDF2 serve as biomarkers of Ewing's sarcoma, and we can use the expression of these two genes in Ewing's sarcoma to predict the survival risk and prognosis of Ewing's sarcoma patients, providing new and useful information to guide clinical diagnosis and treatment.